Enibarcimab for the treatment of septic shock in patients selected by a combination of the biomarkers bio-ADM and DPP3: A prespecified subgroup analysis of the AdrenOSS-2 trial
Loading...
Date
Authors
Knothe, C.
Witte, S.
Bergmann, A.
Mebazaa, A.
Laterre, P.F.
Pickkers, P. Peter